Masimo Unveils Fractional Arterial Oxygen Saturation, SpfO2, and Rainbow SuperSensor


SpfO2 Enables More Accurate Oxygenation Assessment in the Presence of Dyshemoglobins

IRVINE, Calif. - Masimo (NASDAQ: MASI) today announced the CE Mark and debut of the new fractional arterial oxygen saturation, SpfO(2)(TM), parameter through the rainbow® Universal ReSposable SuperSensor(TM), the first noninvasive sensor to provide simultaneous monitoring of SpHb®, SpCO®, SpMet®, SpfO(2), SpOC(TM), Perfusion Index, PVI®, and Measure-Through Motion and Low Perfusion SpO(2) and pulse rate.

Masimo will debut the SpfO(2) and the rainbow® SuperSensor at the American Society of Anesthesiologists' 2012 Annual Meeting in Washington, D.C., tomorrow.

Until now, pulse oximeters could only measure and display functional oxygen saturation (SpO(2)). So, when patients had elevated carboxyhemoglobin (from carbon monoxide poisoning) and/or elevated methemoglobin (negative reaction to more than 30 common drugs used in hospitals, like caines, nitrates, and Dapsone), the displayed functional oxygen saturation overestimated the actual oxygen saturation value.

Utilizing more than seven wavelengths of light and breakthrough signal processing, Masimo rainbow® Pulse CO-Oximeters(TM) can measure and display fractional arterial oxygen saturation (SpfO(2)). SpfO(2)allows more precise arterial oxygenation assessment in patients with elevated dyshemoglobins, common throughout the hospital and pre-hospital setting, compared to functional oxygen saturation (SpO(2)).

SpfO(2) may allow earlier interventions and more timely therapeutic decisions. For example, in a patient who is a smoker with an SpO(2) of 98%, carboxyhemoglobin level of 12% and methemoglobin of 1%, if SpfO(2) were available, it would be displayed at 85%. It is well accepted that clinicians would frequently make different diagnostic and therapeutic decisions at an oxygenation of 85% versus 98%.

"The new fractional arterial oxygenation measurement adds to the unprecedented noninvasive monitoring innovations Masimo has brought to clinicians, providing greater insight into the true state of their patients," said Masimo CEO and founder Joe Kiani. "SpfO(2) will also be used with the noninvasive and continuous hemoglobin (SpHb) measurement, to assess the patient's true arterial oxygen content (SpOC) and should lead to better decisions about common therapies such as administering oxygen or red blood cell transfusions."

Both SpfO(2) and the rainbow® SuperSensor are pending FDA 510(k) clearance.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO(2), pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet(TM), a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring(TM), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa(TM)). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Media Contact:

Mike Drummond

Masimo Corporation

Phone: (949) 297-7434

Email: mdrummond@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

SOURCE

Masimo

Web Site: www.masimo.com

More from Laboratory and Research Supplies and Equipment

All Topics